Autopsy report · NCT01948180

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

“Insufficient enrollment rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 4 years before it stopped.
• 15 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Cell Medica Ltd

Sponsor type

Industry

Conditions

Lymphoma, Extranodal NK-T-Cell; EBV

Interventions

baltaleucel-T

Participants

15

Sites

11

Countries

France, South Korea, United Kingdom, United States

Trials that died the same way

• Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.
  “insufficient enrollment” (91% match in meaning)
• Family Nurture Intervention in the CHoNJ NICU
  “insufficient enrollment numbers” (88% match in meaning)
• Prophylactic Phenobarbital After Neonatal Seizures
  “Inadequate rate of enrollment” (87% match in meaning)
• Treatment Prior to Injection and Biopsy of the Vulva
  “Not enough enrollment” (84% match in meaning)
• Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine
  “Lack of enrollment” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.